Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.

导出 LinkOut

翻译打印收藏纠错

第一作者： Aurélien,Amiot

第一单位： Department of Gastroenterology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France; University of Paris Est Creteil, 94000 Créteil, France; LIC, Laboratoire d'Investigation Clinique EA 4393, 94000 Créteil, France. Electronic address: aurelien.amiot@hmn.aphp.fr.

作者： Aurélien,Amiot ^[1] ; Anne,Hulin ^[2] ; Mehdi,Belhassan ^[3] ; Chantal,Andre ^[4] ; Charlotte,Gagniere ^[3] ; Yann,Le Baleur ^[3] ; Jean-Pierre,Farcet ^[4] ; Jean-Charles,Delchier ^[3] ; Sophie,Hüe ^[4]

作者单位： Department of Gastroenterology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France; University of Paris Est Creteil, 94000 Créteil, France; LIC, Laboratoire d'Investigation Clinique EA 4393, 94000 Créteil, France. Electronic address: aurelien.amiot@hmn.aphp.fr. ^[1] University of Paris Est Creteil, 94000 Créteil, France; Laboratory of Pharmacology-Toxicology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France; Laboratory of Biological Immunology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France. ^[2] Department of Gastroenterology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France; University of Paris Est Creteil, 94000 Créteil, France. ^[3] University of Paris Est Creteil, 94000 Créteil, France; Laboratory of Biological Immunology, Henri-Mondor Hospital, DHU VIC, AP-HP, 94000 Créteil, France; INSERM, Unit U-955, IMRB, 94000 Créteil, France. ^[4]